Organisation paid for research Program year 2025 Source: CMS Open Payments

Allergy Asthma Sinus Center

Neither a doctor nor a teaching hospital

Research payments

$317,711

37 payments

Through program year 2025, Allergy Asthma Sinus Center is reported as receiving $317,711 in research payments, across 37 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$146,594	15
2024	Research	$145,391	16
2023	Research	$15,930	4
2022	Research	$4,943	1
2021	Research	$4,854	1

Breakdown

Who paid Research payments · program years 2021–2025

Genentech, Inc. $219,788 29 payments
Novartis Pharmaceuticals Corporation $97,923 8 payments

Studies the money was for Research payments · program years 2021–2025

PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $162,617 18 payments
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal and Open-Label Extension Study Followed By Long-Term Open-Label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (Lou064) in Adult Chronic Spontaneous U $80,825 2 payments
Ph III OLE of Astegolimab in COPD $57,171 11 payments
A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study to Assess the Efficacy and Safety of Csj117, When Added to Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. $9,796 2 payments
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies $4,756 2 payments
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks $2,546 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.